 PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 GLOBE NEWSWIRE -- NeuBase Therapeutics, Inc. Nasdaq: NBSE NeuBase or the Company, a biotechnology platform company Drugging the GenomeTM to address disease at the base level using a new class of precision genetic medicines, announced today that company management will participate in a fireside chat and will be available for one-on-one meetings at Oppenheimers 32nd Annual Healthcare Conference being held virtually March 15 17, 2022. 